Lantern Pharma Splits Its Engines: Open Medicine AI Spinout Marks a New Era
Clinical progress and a strategic separation define a decisive quarter for the micro-cap oncology developer.
LTRN · Earnings Call · 2026-08-14
The Structural Pivot: Open Medicine AI
The most consequential move this quarter was the creation of Open Medicine AI (OMAI) as a separately capitalized company, with Lantern holding 100% ownership and executing board-approved commercial licensing agreements. The logic is clear: clinical drug development and enterprise software are valued by different investor bases, and holding an AI platform inside a clinical-stage biotech risks underpricing the asset. As CEO Panna Sharma put it, the move reflects a conviction that “that is exactly where I see open medicine playing. Is a new category that just has not been valued and priced” — Panna Sharma, Chief Executive Officer · 2026-08-14. The platform, built as a multi-agentic "coscientist" called RADR withZeta, is now commercially accessible and already attracting interest from large pharma – a validation that the market is warming to Agentic AI in drug discovery. This is not a whim; it builds on years of groundwork. In the November 2024 call, Sharma had already signaled the blueprint: “We think this could be one of several planned spinouts from Lantern where the portfolio is more focused” — A - Panna Sharma, Investor Relations or Communications · 2024-11-08 — referencing Starlight. Now the same template is being applied to the AI engine itself, a move that could unlock a very different valuation multiple.Clinical Maturation: LP-300, LP-184, and the Patent Estate
LP-300, the Phase 2 HARMONIC trial in non-small cell lung cancer, delivered a sharpened signal. Data as of the May 11 cutoff showed that among L858R patients completing six cycles, median progression-free survival reached 8.9 months, with a hazard ratio of 0.37. The trial has been amended to concentrate on L858R patients, extend treatment to eight cycles, and shift to a single-arm design for efficiency. Enrollment resumes in the U.S. and Taiwan, and the company expects 15–16 additional patients over the next 4–6 months. As Sharma emphasized, “A drug that helps more the longer you stay on it without costing you more in side effects is a drug worth extending” — Panna Sharma, Chief Executive Officer · 2026-08-14. LP-184 also advanced on multiple fronts: EMA clearance for an investigator-initiated Phase 1b/2 trial in bladder cancer (with a dual PTGR1/DDR biomarker strategy), FDA clearance for a relapsed/refractory triple-negative breast cancer trial, and a notice of allowance for a 3-gene patient-selection patent covering ovarian, liver, kidney, and thyroid cancers. The company now holds four rare-pediatric disease designations under STARLIGHT (the LP-184 brain cancer program), each eligible for priority review vouchers. This growing intellectual-property estate underpins the platform's value proposition: every clinical milestone is a validation of the AI-driven selection logic.Financial Discipline amid Rising Non-Cash Costs
Financially, the quarter showed a 25% year-over-year reduction in loss from operations, with R&D expenses down 42% to $1.8M. However, a substantial non-cash warrant expense of $3.6M (driven by the stock-price surge after the May financing) pushed net loss to $7.1M. CFO David Margrave was explicit about the accounting mechanics, but the headline number masks the underlying discipline. The company's cash position sits at $7.4M, enough for only ~1.7 quarters of runway at the current burn — a stark reminder that cash runway is the binding constraint. The company intends to pursue additional capital raises, collaborations, and spinout financing to extend the runway.The golden age of artificial intelligence in medicine is not beginning. it is actually accelerating. And this quarter, that idea has resulted in the development of a new company, Open Medicine AI.